- Posted 10 September 2025
- LocationUnited States of America
- Job type Contract
- Reference222524
CRA
Job description
Contract Senior CRA โ Oncology (12-Month Contract, UK Remote)
(Outside IR35) | ๐ UK Remote | ๐งช Phase III Solid Tumor Trial
We are partnering with a fast-growing, innovative biotechnology company advancing cutting-edge immuno-oncology therapies. As they scale their pivotal Phase III Solid Tumor study, they are seeking an experienced Contract Clinical Research Associate (CRA) to join their UK team.
This is a fantastic opportunity to work on a high-profile, late-phase oncology trial with a sponsor who values collaboration, innovation, and clinical excellence.
The Role
-
Contract length: 12 months (with strong potential for extension)
-
Therapeutic area: Oncology โ Solid Tumors (Phase III)
-
Coverage: 11 UK sites, supported by a team of 2 CRAs
-
Location: Remote (UK-based), with routine travel to sites
-
Engagement: Outside IR35
Responsibilities
-
Conduct routine on-site and remote monitoring (PSV, SIV, IMV, COV) across multiple UK sites.
-
Ensure full compliance with ICH-GCP, study protocol, and sponsor SOPs.
-
Maintain strong relationships with investigators and site staff to drive recruitment and data quality.
-
Oversee SDV/SDR, query resolution, and timely site documentation updates in eTMF.
-
Support audit/inspection readiness, corrective/preventive actions (CAPAs), and risk-based monitoring activities.
Requirements
-
5+ years CRA experience, with a strong background in oncology trials (solid tumor preferred).
-
Proven expertise in Phase II/III oncology studies within the UK.
-
Ability to independently manage multiple sites and ensure timely study deliverables.
-
Strong working knowledge of EDC systems (Medidata Rave preferred), CTMS, and eTMF.
-
UK-based, with flexibility to travel across assigned sites.
Why Apply?
-
Join a sponsor-driven study rather than a CRO environment โ your impact will be felt directly on trial outcomes.
-
Contribute to a pivotal Phase III oncology program that has the potential to change treatment landscapes.
-
Competitive outside IR35 contract rate with long-term engagement potential.